NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SRPT

Sarepta Therapeutics Inc

Jun 20 • 04:00PM ET

20.08

Dollar change -0.69
Percentage change -3.32	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN ALNY IONS PFE PTCT EXEL PRTA BLUE RDUS

| Held by: VTI VB IJH VXF VBK XBI MDY FBT IJK IBB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.58	Insider Own	4.99%	Shs Outstand	98.25M	Perf Week	-46.18%
Market Cap	1.97B	Forward P/E	7.31	EPS next Y	2.75	Insider Trans	-0.05%	Shs Float	93.37M	Perf Month	-49.79%
Enterprise Value	2.79B	PEG	-	EPS next Q	0.68	Inst Own	90.15%	Short Float	9.92%	Perf Quarter	-72.66%
Income	-248.39M	P/S	0.88	EPS this Y	-272.66%	Inst Trans	-0.96%	Short Ratio	1.99	Perf Half Y	-84.16%
Sales	2.23B	P/B	1.73	EPS next Y	172.92%	ROA	-7.43%	Short Interest	9.26M	Perf YTD	-83.49%
Book/sh	11.63	P/C	3.77	EPS next 5Y	19.75%	ROE	-23.61%	52W Range	18.30 - 173.25	Perf Year	-82.81%
Cash/sh	5.32	P/FCF	-	EPS past 3/5Y	- -	ROIC	-9.99%	52W High	-88.41%	Perf 3Y	-70.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.42% 37.94%	Gross Margin	80.07%	52W Low	9.73%	Perf 5Y	-87.36%
Dividend TTM	-	EV/Sales	1.25	EPS Y/Y TTM	-1881.09%	Oper. Margin	-5.25%	Volatility	26.82% 12.60%	Perf 10Y	-28.59%
Dividend Ex-Date	-	Quick Ratio	2.46	Sales Y/Y TTM	59.15%	Profit Margin	-11.12%	RSI (14)	20.47	Recom	2.07
Dividend Gr. 3/5Y	- -	Current Ratio	4.02	EPS Q/Q	-1361.33%	SMA20	-42.65%	Beta	0.60	Target Price	54.00
Payout	0.00%	Debt/Eq	1.18	Sales Q/Q	80.15%	SMA50	-54.35%	Rel Volume	2.71	Prev Close	20.77
Employees	1372	LT Debt/Eq	1.18	Earnings	May 06 AMC	SMA200	-79.13%	Avg Volume	4.65M	Price	20.08
IPO	Jun 04, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	-43.44% 8.35%	Trades		Volume	12,622,926	Change	-3.32%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-20-25	Downgrade	William Blair	Outperform → Mkt Perform
Jun-18-25	Downgrade	TD Cowen	Buy → Hold	$24
Jun-17-25	Initiated	Wolfe Research	Peer Perform
Jun-16-25	Downgrade	Piper Sandler	Overweight → Neutral	$36
Jun-16-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-16-25	Downgrade	H.C. Wainwright	Neutral → Sell	$10
Jun-16-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-16-25	Downgrade	BofA Securities	Buy → Neutral
Jun-16-25	Downgrade	BMO Capital Markets	Outperform → Market Perform	$70
Jun-06-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
May-08-25	Downgrade	Evercore ISI	Outperform → In-line	$50
Apr-11-25	Initiated	Wells Fargo	Overweight	$115
Apr-02-25	Upgrade	H.C. Wainwright	Sell → Neutral	$75
Mar-31-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$161 → $87
Feb-11-25	Initiated	Deutsche Bank	Hold	$136
Nov-27-24	Reiterated	Needham	Buy	$205 → $202
Nov-25-24	Initiated	H.C. Wainwright	Sell	$80
Nov-07-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$152 → $167
Oct-21-24	Initiated	Jefferies	Buy	$165
Oct-10-24	Resumed	Raymond James	Outperform	$150

Show Previous Ratings

Jun-20-25 04:08PM	The FDA Shake-Up Continues, And Could Impact Genetic Medicines (Investor's Business Daily)
11:56AM	Gene Therapy Stocks Fall as FDA Pushes Out Another Top Regulator (Barrons.com)
11:56AM	Gene Therapy Stocks Fall Amid More Turmoil at FDA (Barrons.com)
11:27AM	Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street. (Barrons.com)
Jun-19-25 09:45AM	SanDisk initiated, Analog Devices upgraded: Wall Streets top analyst calls (TipRanks)
03:00AM	Loading…
03:00AM	Gene Therapy Has Lost Support on Wall Street. There's Still Hope for Big Cures. (Barrons.com)
Jun-18-25 11:39AM	Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences (MarketBeat)
09:51AM	Roku upgraded, Sarepta downgraded: Wall Streets top analyst calls (TipRanks)
Jun-17-25 09:35AM	Cisco upgraded, CoreWeave downgraded: Wall Streets top analyst calls (TipRanks)
09:23AM	Company News for Jun 17, 2025 (Zacks)
09:16AM	Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus (TipRanks)
06:20AM	Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? (Zacks)
Jun-16-25 05:07PM	Stocks to Watch Recap: U.S. Steel, Kraft Heinz, Circle, Warner Bros. (The Wall Street Journal) -42.12%
04:19PM	Sarepta Crashes To Nine-Year Low After A Second Gene Therapy Patient Dies (Investor's Business Daily)
04:13PM	These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More (Barrons.com)
04:05PM	Loading…
04:05PM	Second patient death reported with gene therapy for muscular dystrophy (Associated Press Finance)
03:51PM	AMD pops, Sarepta tanks, EchoStar & Trump: Trending Tickers (Yahoo Finance Video)
03:15PM	Stocks Rise as Fear of All-Out Mideast War Eases: Markets Wrap (Bloomberg)
02:31PM	These Stocks Are Moving the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More (Barrons.com)
01:37PM	Stocks to Watch: U.S. Steel, Reddit, Circle, Warner Bros. (The Wall Street Journal)
12:30PM	Why Sarepta Therapeutics (SRPT) Stock Is Down Today (StockStory)
12:19PM	Strategy buys $1B of bitcoin, Echostar jumps, Sarepta plunges (Yahoo Finance Video)
11:59AM	Top Stock Movers Now: United Airlines, AMD, Lockheed Martin, and More (Investopedia)
11:10AM	Sarepta Therapeutics Plummets 46% After A Second Gene Therapy Recipient Dies (Investor's Business Daily)
10:24AM	Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug (Investopedia)
09:12AM	Sarepta down analysts flag risks after second Elevidys-linked death (Investing.com)
08:45AM	SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion (Zacks)
08:00AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:55AM	Sarepta and Roche halt DMD gene therapys use after second death (Pharmaceutical Technology)
06:18AM	Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy (Barrons.com)
05:18AM	Loading…
05:18AM	These Stocks Are Moving the Most Today: Sarepta, Tesla, U.S. Steel, Victoria's Secret, Lennar, and More (Barrons.com)
05:17AM	Sarepta plunges, U.S. Steel rises and other movers (MarketWatch)
Jun-15-25 01:00AM	Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne (Business Wire)
Jun-10-25 12:31PM	Sarepta Therapeutics' (SRPT) Rating Downgrade Dents Share Price (Insider Monkey)
12:38AM	1 Unprofitable Stock for Long-Term Investors and 2 to Ignore (StockStory)
Jun-07-25 09:40AM	CrowdStrike and McDonalds downgraded: Wall Streets top analyst calls (TipRanks)
Jun-05-25 05:39PM	The FDA granted Sarepta's rAAVrh74 Viral Vector a Platform Technology Designation (Insider Monkey) +9.69%
11:31AM	Why Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report? (Zacks)
10:03AM	FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector (Zacks)
Jun-04-25 01:00PM	FDA to use new review tool on Sareptas gene therapy work (BioPharma Dive)
09:30AM	U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sareptas Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4 (Business Wire)
May-27-25 10:03AM	Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)? (Insider Monkey)
May-22-25 06:52AM	FDA advisers pan Pfizers PARP drug; Sarepta to resume Duchenne study (BioPharma Dive)
May-21-25 08:30AM	Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy (Business Wire)
May-19-25 10:04AM	SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays (StockStory)
07:36AM	Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy (Clinical Trials Arena)
May-16-25 09:01AM	Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment (Business Wire)
09:00AM	Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2 (Business Wire)
May-14-25 08:30AM	Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn't Ignore (MarketBeat)
May-13-25 09:25AM	Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy (Business Wire)
04:14AM	2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying (Motley Fool)
May-11-25 04:41PM	Sarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin's Stock Picks with Huge Upside Potential (Insider Monkey)
May-09-25 12:01PM	Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz (TipRanks)
08:48AM	Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back? (Insider Monkey)
May-08-25 04:30PM	Sarepta Therapeutics to Present at the BofA Securities Health Care Conference (Business Wire)
10:36AM	Sarepta price target lowered to $125 from $183 at Needham (TipRanks)
05:01AM	Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday (Insider Monkey)
May-07-25 04:17PM	The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low (Investor's Business Daily) -21.45%
02:14PM	Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating (Seeking Alpha)
01:32PM	Sarepta Therapeutics Stock Plunges on Guidance Cut. Its Moneymaker Is Under Fire. (Barrons.com)
12:14PM	Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade (Seeking Alpha)
11:25AM	Nebius Group, Oscar Health Q1 earnings, Sarepta cuts outlook (Yahoo Finance Video)
09:41AM	Q1 2025 Sarepta Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:31AM	SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut (Zacks)
07:46AM	Sarepta stock plummets as lower sales outlook adds to gloom over FDAs new biologics hire (BioPharma Dive)
07:46AM	Sarepta shares plummet as lower sales outlook adds to gloom over FDAs new biologics hire (BioPharma Dive)
07:29AM	Sarepta shares fall amid FDAs CBER appointment and weak Elevidys sales (Pharmaceutical Technology)
03:19AM	Sarepta Therapeutics Inc (SRPT) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ... (GuruFocus.com)
May-06-25 10:41PM	Sarepta Therapeutics, Inc. (SRPT) Q1 2025 Earnings Call Transcript (Seeking Alpha) -26.56%
06:00PM	Compared to Estimates, Sarepta Therapeutics (SRPT) Q1 Earnings: A Look at Key Metrics (Zacks)
05:35PM	Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments (Business Wire)
May-05-25 08:00AM	Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict (Seeking Alpha)
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
May-04-25 06:46AM	Oppenheimer Predicts Up to ~840% Surge for These 2 Strong Buy Stocks (TipRanks)
May-01-25 12:36AM	1 of Wall Street's Favorite Stock on Our Buy List and 2 to Approach with Caution (StockStory)
Apr-30-25 10:01AM	Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-29-25 08:24PM	Why Sarepta Therapeutics, Inc. (SRPT) is Among the Best Oversold NASDAQ Stocks to Buy Right Now (Insider Monkey)
10:01AM	Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-24-25 07:54AM	Sarepta Therapeutics (SRPT): Among Billionaire George Soros' Small-Cap Stocks with Huge Upside Potential (Insider Monkey)
Apr-22-25 08:30AM	Sarepta Therapeutics to Announce First Quarter 2025 Financial Results (Business Wire) +7.39%
Apr-21-25 10:19PM	Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts? (Insider Monkey)
04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily)
Apr-16-25 07:32AM	SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies (Zacks)
Apr-15-25 08:30AM	Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs (Business Wire)
Apr-11-25 02:13PM	Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation (Seeking Alpha)
Apr-10-25 05:00AM	The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb (Zacks) -9.60%
Apr-09-25 01:45PM	Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More (Zacks) +12.88%
Apr-08-25 04:50PM	Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space (Seeking Alpha) -5.92%
07:30AM	Can Solid Biosciences Challenge Sarepta in the DMD Market? (MarketBeat)
05:14AM	3 Reasons to Avoid SRPT and 1 Stock to Buy Instead (StockStory)
Apr-07-25 08:09AM	4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street (Motley Fool)
07:21AM	Sarepta and Roche aim to resume paused Elevidys trials following patient death (Clinical Trials Arena)
Apr-04-25 10:38AM	Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death (Investopedia) -7.13%
09:25AM	Sarepta price target lowered to $183 from $202 at Needham (TipRanks)
08:44AM	Sarepta Therapeutics Provides Update on ELEVIDYS (Business Wire)
07:29AM	SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy (Zacks)
Apr-03-25 04:27PM	Sarepta Dives On 'Another Unfortunate Development' For Its Gene Therapy (Investor's Business Daily) -6.18%
03:37PM	BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion (Seeking Alpha)
03:23PM	Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death (Benzinga)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barry Richard	Director	May 16 '25	Option Exercise	32.63	12,350	402,981	2,966,667	May 19 07:32 AM
Barry Richard	Director	May 13 '25	Option Exercise	19.23	20,246	389,359	2,954,317	May 15 07:00 AM
Nicaise Claude	Director	Mar 12 '25	Option Exercise	25.18	9,746	245,404	30,303	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Sale	99.64	2,491	248,203	27,812	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Proposed Sale	99.65	2,491	248,226		Mar 12 05:33 PM
Estepan Ian Michael	Chief Financial Officer	Jan 29 '25	Option Exercise	12.00	15,800	189,600	49,496	Jan 31 08:30 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Option Exercise	13.71	10,500	143,955	33,340	Dec 16 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Sale	124.84	10,500	1,310,820	22,840	Dec 16 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Proposed Sale	124.80	10,500	1,310,400		Dec 12 05:06 PM
Boor Kathryn Jean	Director	Dec 05 '24	Sale	125.55	1,636	205,400	5,880	Dec 06 08:00 PM
Boor Kathryn Jean	Director	Dec 05 '24	Proposed Sale	125.55	1,636	205,400		Dec 05 04:18 PM
Estepan Ian Michael	Chief Financial Officer	Aug 30 '24	Sale	137.36	5,985	822,100	33,946	Sep 03 08:00 PM
Estepan Ian Michael	Officer	Aug 30 '24	Proposed Sale	137.37	5,985	822,130		Aug 30 05:03 PM
Chambers Michael Andrew	Director	Aug 16 '24	Buy	133.80	37,038	4,955,728	284,034	Aug 20 08:00 AM
BEHRENS M KATHLEEN	Director	Jul 03 '24	Option Exercise	13.90	15,000	208,500	191,839	Jul 08 08:00 PM
Brown Ryan Edward	EVP, General Counsel	Jun 25 '24	Option Exercise	62.77	23,500	1,475,095	56,086	Jun 25 08:00 PM
Brown Ryan Edward	EVP, General Counsel	Jun 25 '24	Sale	161.61	38,957	6,296,029	17,129	Jun 25 08:00 PM
Arif Bilal	Chief Tech Ops Officer	Jun 24 '24	Sale	163.08	7,859	1,281,621	21,261	Jun 25 08:00 PM
Arif Bilal	Chief Tech Ops Officer	Jun 25 '24	Sale	163.23	3,898	636,271	17,363	Jun 25 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRPT

Sarepta Therapeutics Inc

Upgrade your FINVIZ experience